Media » The Medicines Patent Pool and Mylan sign agreement to scale up access to first generic version of hepatitis C treatment glecaprevir/pibrentasvir

The Medicines Patent Pool and Mylan sign agreement to scale up access to first generic version of hepatitis C treatment glecaprevir/pibrentasvir

Geneva, 20 February 2020 – The Medicines Patent Pool (MPP) today announced that it signed a sublicence agreement and partnered with Mylan, a global pharmaceutical company, to develop, manufacture and supply the first generic version of glecaprevir/pibrentasvir (G/P) – a World Health Organization (WHO)-recommended treatment for hepatitis C virus (HCV)infections.

G/P is the only all oral, once-daily pan-genotypic combination regimen recommended by WHO that is currently not available as a generic medicine. The two organisations have entered an agreement to undertake G/P manufacturing henceforth and boost the supply to make it accessible to Hepatitis C patients.

“We are pleased that, thanks to this sublicence agreement, Mylan will soon be able to increase access to the first generic version of G/P in developing countries, and supply affordable, quality-assured versions of this key treatment for treating HCV,” said Charles Gore, MPP Executive Director.

In November 2018, MPP signed a royalty-free licence agreement with patent holder AbbVie to enable quality-assured manufacturers to develop and sell generic medicines containing G/P in 96 low- and middle-income countries and territories at affordable prices.

More information on glecaprevir/pibrentasvir (G/P)

Access MPP-Mylan sublicence agreement

Access MPP-Abbvie licence agreement

This website uses cookies to ensure you get the best experience on our website. Learn More